InvestorsHub Logo
Post# of 252311
Next 10
Followers 0
Posts 113
Boards Moderated 0
Alias Born 05/28/2005

Re: masterlongevity post# 169933

Wednesday, 11/13/2013 3:17:45 PM

Wednesday, November 13, 2013 3:17:45 PM

Post# of 252311
It's hard to compare. The ibrutinib patient pop failed chop-Rituxan (with or without Rituxan maintenance) and potentially velcade (50 of the 115 pts). OR was 68%, CR - 21%, PFS - 13.9 mo

http://www.nejm.org/doi/full/10.1056/NEJMoa1306220


A better comparison might be velcade in a similar (slightly less heavily pre-treated pop)--TTP -6.7 mo

http://www.ncbi.nlm.nih.gov/pubmed/19074748

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.